•
Oct 02, 2021

Waters Q3 2021 Earnings Report

Waters reported an 11% increase in sales and a rise in both GAAP and non-GAAP EPS, driven by strong performance in the pharmaceutical and industrial end markets.

Key Takeaways

Waters Corporation reported Q3 2021 sales of $659 million, an 11% increase compared to Q3 2020. GAAP EPS increased to $2.60, and non-GAAP EPS increased to $2.66. The company saw strong growth in pharmaceutical and industrial end markets and balanced customer demand across the Americas, Europe, and Asia.

Sales of $659 million grew 11% as reported and in constant currency.

GAAP EPS of $2.60; non-GAAP EPS of $2.66, a 23% increase from prior year.

Growth was led by strong performance in pharmaceutical and industrial end markets.

There was double-digit growth in both instrument sales and recurring revenues.

Total Revenue
$659M
Previous year: $594M
+11.0%
EPS
$2.66
Previous year: $2.16
+23.1%
Pharma Market Sales
16%
Previous year: 5%
+220.0%
Industrial Market Sales
9%
Previous year: 5%
+80.0%
Academic & Gov Sales
-9%
Previous year: -8%
+12.5%
Gross Profit
$388M
Previous year: $331M
+17.1%
Cash and Equivalents
$525M
Previous year: $375M
+39.9%
Total Assets
$3.12B
Previous year: $2.68B
+16.3%

Waters

Waters

Waters Revenue by Geographic Location

Forward Guidance

The Company expects full-year 2021 constant-currency sales growth in the range of 15% to 16%. Currency translation is expected to increase full-year sales growth by approximately one percentage point. The Company expects full-year 2021 non-GAAP EPS in the range of $10.94 to $11.04. The Company expects fourth quarter 2021 constant-currency sales growth in the range of 5% to 7%. Currency translation is expected to decrease fourth quarter sales growth by approximately two percentage points. The Company expects fourth quarter 2021 non-GAAP EPS in the range of $3.40 to $3.50.

Revenue & Expenses

Visualization of income flow from segment revenue to net income